Effect of NIP-142 on potassium channel α-subunits Kv1.5, Kv4.2 and Kv4.3, and mouse atrial repolarization

Biological and Pharmaceutical Bulletin

Volumn 33, Issue 1, 2010, Pages 138-141

  Tanaka, Hikaru ^a   Namekata, Iyuki ^a   Hamaguchi, Shogo ^a   Kawamura, Taro ^a   Masuda, Hiroyuki ^a   Tanaka, Yoshio ^a   Iida Tanaka, Naoko ^a,b   Takahara, Akira ^a  

^a TOHO UNIVERSITY   (Japan)

^b OTSUMA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Atrial fibrillation; Kv1.5; Kv4.2; Kv4.3; NIP 142

Indexed keywords

BENZOPYRAN DERIVATIVE; COMPLEMENTARY DNA; NIP 142; POTASSIUM CHANNEL KV1.5; POTASSIUM CHANNEL KV4.2; POTASSIUM CHANNEL KV4.3; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CELL MEMBRANE DEPOLARIZATION; CLONING; DRUG MECHANISM; GENE AMPLIFICATION; HEART ATRIUM ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CONTRACTILITY; HEART REPOLARIZATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYTE; POLYMERASE CHAIN REACTION; REFRACTORY PERIOD; XENOPUS;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BENZOPYRANS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART ATRIA; MICE; MUSCLE CONTRACTION; MYOCARDIUM; OOCYTES; SHAKER SUPERFAMILY OF POTASSIUM CHANNELS; XENOPUS;

EID: 75149174741     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.33.138     Document Type: Article

References (21)

1. Sugimoto T., Hayakawa K. and Kasanuki H., "Atrial Fibrillation, Flutter, and Tachycardia," ed. by Hayakawa K., Kasanuki H., Igaku-Shoin, Tokyo, 1999, pp. 14-18.
2. Aliot E., Denjoy I., Am. J. Cardiol., 77, 66A-71A (1996).
3. Iwasaki H., Takahara A., Nakamura Y., Satoh Y., Nagai T., Shinkai N., Sugiyama A., J. Pharmacol. Sci., 110, 410-414 (2009).
4. Lenz T., Hilleman D., Drugs Today (Barc), 36, 759-771 (2000).
5. Nagasawa H., Fujiki A., Fujikura N., Matsuda T., Yamashita T., Inoue H., Circ. J., 66, 185-191 (2002).
6. Matsuda T., Takeda K., Ito M., Yamagishi R., Tamura M., Nakamura H., Tsuruoka N., Saito T., Masumiya H., Suzuki T., Iida-Tanaka N., Itokawa M., Yamashita T., Tsuruzoe N., Tanaka H., Shigenobu K., J. Pharmacol. Sci., 98, 33-40 (2005).
7. Seki A., Hagiwara N., Kasanuki H., J. Cardiovasc. Pharmacol., 39, 29-38 (2002).
8. Matsuda T., Ito M., Ishimaru S., Tsuruoka N., Saito T., Iida-Tanaka N., Hashimoto N., Yamashita T., Tsuruzoe N., Tanaka H., Shigenobu K., J. Pharmacol. Sci., 101, 303-310 (2006).
9. Nishimaru K., Makuta R., Tanaka Y., Tanaka H., Shigenobu K.. Pharmacology, 62, 87-91 (2001).
10. Matsuda T., Masumiya H., Tanaka N., Yamashita T., Tsuruzoe N., Tanaka Y., Tanaka H., Shigenobu K., Life Sci., 68, 2017-2024 (2001).
11. Gaborit N., Bouter S.L., Szuts V., Varro A., Escande D., Nattel S., Demolombe S., J. Physiol., 582, 675-693 (2007).
12. Trépanier-Boulay V., Lupien M., St-Michel C., Fiset C., Cardiovasc. Res., 64, 84-93 (2004).
13. Wang Y., Xu H., Kumar R., Tipparaju S. M., Wagner M. B., Joyner R. W., J. Mol. Cell. Cardiol., 35, 1083-1092 (2003).
14. Oudit G. Y., Kassiri Z., Sah R., Ramirez R. J., Zobel C., Backx P. H., J. Mol. Cell. Cardiol., 33, 851-872 (2001).
15. Tanaka H., Namekata I., Nouchi H., Shigenobu K., Kawanishi T., Takahara A., J. Pharmacol. Sci., 109, 327-333 (2009).
16. Fukuda T., Yamashita T., Sagara K., Kato T., Sawada H., Aizawa T., Circ. J., 71, 308-312 (2007).
17. Kalifa J., Jalife J., Zaitsev A. V., Bagwe S., Warren M., Moreno J., Berenfeld O., Nattel S., Circulation, 108, 668-671 (2003).
18. Qi J., Xiao J., Zhang Y., Li J., Liu Y., Li P., Liang L., Jiang B., Wen W., Zhao C., Liang D., Liu Y., Chen Y. H., Exp. Biol. Med., 234, 779-784 (2009).
19. Fatkin D., Kelly R. P., Feneley M. P., J. Am. Coll. Cardiol., 23, 961-969 (1994).
20. Mugge A., Kuhn H., Nikutta P., Grote J., Lopez J. A., Daniel W. G., J. Am. Coll. Cardiol., 23, 599-607 (1994).
21. deHaan S., Greiser M., Harks E., Blaauw Y., Hunnik A., Verheule S., Allessie M., Schotten U., Circulation, 114, 1234-1242 (2006).